Visual Universitätsmedizin Mainz

Publikationsliste

2018

Bartkowiak, D., Buehrdel, S., Wiegel, T., Wollschlaeger, D., Merzenich, H., Blettner, M., Karle, H., Stockinger, M., Schmidberger, H., Schmidt, M., et al. (2018a). Lack of evidence for cardiac effects of breast cancer irradiation. Strahlenther. Onkol. 194, S82–S83.


Bartkowiak, D., Merzenich, H., Wollschlager, D., Karle, H., Stockinger, M., Schmidt, M., Blettner, M., Schmidberger, H., Wockel, A., Janni, W., et al. (2018b). Results from the PASSOS heart study. Oncol. Res. Treat. 41, 1–1.


Bartlett, J.M.S., Bayani, J., Kornaga, E., Piper, T., Mallon, E., Yao, C.Q., Boutros, P.C., Hasenburg, A., Kieback, D.G., Markopoulos, C., et al. (2018a). Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree? Cancer Res. 78.


Bartlett, J.M.S., Thomas, J., Mallon, E., Piper, T., Bayani, J., Hasenburg, A., Kieback, D.G., Markopoulos, C., Dirix, L., Seynaeve, C., et al. (2018b). Simplified histological grading of breast carcinoma - potential for improved concordance and consistency in breast cancer grading? Cancer Res. 78.


Bayani, J., Crozier, C., Quintayo, M.A., Amemiya, Y., Zhang, X., Lariviere, M., Sadis, S., Smith, J.M., Hasenburg, A., Kieback, D., et al. (2018a). Evaluation of the oncomine comprehensive assay for the identification of actionable mutations for therapeutic stratification from the TEAM pathology cohort. Cancer Res. 78.


Bayani, J., Kornaga, E.N., Crozier, C., Jang, G.H., Kalatskaya, I., Trinh, Q.M., Yao, C.Q., Livingstone, J., Hasenburg, A., Kieback, D.G., et al. (2018b). Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. Cancer Res. 78.


de Boniface, J., Schmidt, M., Engel, J., Smidt, M.L., Offersen, B.V., and Reimer, T. (2018). What Is the Best Management of cN0pN1(sn) Breast Cancer Patients? Breast Care 13, 331–336.
Breuksch, I., Welter, J., Bauer, H.-K., Enklaar, T., Frees, S., Thüroff, J.W., Hasenburg, A., Prawitt, D., and Brenner, W. (2018). In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself. Cell Communication and Signaling 16.


Chekerov, R., Hilpert, F., Mahner, S., El-Balat, A., Harter, P., De Gregorio, N., Fridrich, C., Markmann, S., Potenberg, J., Lorenz, R., et al. (2018). Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology 19, 1247–1258.


Coombes, R.C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., et al. (2018). A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). Cancer Res. 78.


Derks, M.G.M., Bastiaannet, E., van de Water, W., de Glas, N.A., Seynaeve, C., Putter, H., Nortier, J.W.R., Rea, D., Hasenburg, A., Markopoulos, C., et al. (2018). Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. European Journal of Cancer 99, 1–8.


Eckes, L., Droge, L.A., Fullborn, T., Harter, P., Mustea, A., Muallem, M.Z., Wimberger, P., Mahner, S., Kurzeder, C., Hasenburg, A., et al. (2018). Management of patients with gynecological sarcoma - a survery among gynecologists within the framework of the German Registry of Gynecological Sarcoma (REGSA). Oncol. Res. Treat. 41, 194–195.


Feiten, S., Scholl, I., Schmidt, M., Duennebacke, J., Franzen, A., Ernst, W., and Weide, R. (2018). Shared decision making (SDM) in routine care treatment of breast cancer patients - a survey of patients following surgery. Cancer Res. 78.


Frees, S., Breuksch, I., Haber, T., Bauer, H.-K., Chavez-Munoz, C., Raven, P., Moskalev, I., D´Costa, N., Tan, Z., Daugaard, M., et al. (2018). Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget 9.


Galetzka, D., Boeck, J., Dittrich, M., Zahnreich, S., Altebockwinkel, I., Sinizyn, O., Rossmann, H., Spix, C., Breuksch, I., Prawitt, D., et al. (2018). Factors leading to changes in methylation of intron 2 in RAD9A gene and their possible influence in tumor development. Strahlenther. Onkol. 194, S56–S56.


de Gregorio, N., Harter, P., Kimmig, R., Reuss, A., Pfisterer, J., Hilpert, F., Meier, W., Hanker, L., Canzler, U., Sehouli, J., et al. (2018). Overall survival results of AGO-OVAR 12, a randomized placebo-controlled multinational phase III trial with chemotherapy plus /- nintedanib in patients with advanced primary ovarian cancer. Oncol. Res. Treat. 41, 88–88.


Hartmann, K., Schlombs, K., Laible, M., Gürtler, C., Schmidt, M., Sahin, U., and Lehr, H.-A. (2018). Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagnostic Pathology 13.
Hasenburg, A. (2018). Primary Therapy of Ovarian Cancer. Gynakologe 51, 598–598.


Hasenburg, A., Harter, P., Park-Simon, T.-W., Gropp-Meier, M., Heitz, F., Soergel, P., Ataseven, B., Friedlaender, M., Hilpert, F., and Pujade-Lauraine, E. (2018a). Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III. Oncol. Res. Treat. 41, 88–89.


Hasenburg, A., Sehouli, J., Lampe, B., Reuss, A., Schmalfeldt, B., and Belau, A.K. (2018b). LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women-Prospective substudy of the randomized multicenter LION study. J. Clin. Oncol. 36.


Heimes, A.-S., Jaekel, J., Weyer-Elberich, V., Almstedt, K., Krajnak, S., Elger, T., Brenner, W., Schmidt, M., Hasenburg, A., and Battista, M. (2018). A retrospective analysis of immunohistochemically determined IRF4 expression in a consecutive cohort of 114 ovarian cancer patients. Oncol. Res. Treat. 41, 92–92.


Heitz, F., Harter, P., Kimmig, R., Reuss, A., Gregorio, N.D., Pfisterer, J., Hilpert, F., Meier, W., Hanker, L., Canzler, U., et al. (2018). The prognostic value of tumor residuals (TR) indicated by surgeon (SA), by radiology (RA), or an integrated approach (IA) by surgeons’ assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO led Intergroup trial AGO-OVAR 12. Oncol. Res. Treat. 41, 12–12.


Hillemanns, P., Sehouli, J., Harter, P., Reuss, A., Meier, W., Hasenburg, A., Hilpert, F., Neuenhoeffer, T., Denschlag, D., Burges, A., et al. (2018). Phase III Randomized Controlled Study to Evaluate the Impact of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer - AGO Desktop III / ENGOT OV20. Oncol. Res. Treat. 41, 11–11.


Honecker, F., Harbeck, N., Schnabel, C., Wedding, U., Waldenmaier, D., Saupe, S., Jaeger, E., Schmidt, M., Kreienberg, R., Mueller, L., et al. (2018). Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J. Geriatr. Oncol. 9, 163–169.


Huebner, H., Fasching, P.A., Gumbrecht, W., Jud, S., Rauh, C., Matzas, M., Paulicka, P., Friedrich, K., Lux, M.P., Volz, B., et al. (2018). Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer 18.


Huss, A., Ihorst, G., Timme-Bronsert, S., Hasenburg, A., Oehler, M.K., and Klar, M. (2018). The Memorial Sloan Kettering Cancer Center Nomogram is More Accurate than the 2009 FIGO Staging System in the Prediction of Overall Survival in a German Endometrial Cancer Patient Cohort. Ann. Surg. Oncol. 25, 3966–3973.


Kebenko, M., Goebeler, M.-E., Wolf, M., Hasenburg, A., Seggewiss-Bernhardt, R., Ritter, B., Rautenberg, B., Atanackovic, D., Kratzer, A., Rottman, J.B., et al. (2018). A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. OncoImmunology e1450710.


Kiweler, N., Brill, B., Wirth, M., Breuksch, I., Laguna, T., Dietrich, C., Strand, S., Schneider, G., Groner, B., Butter, F., et al. (2018). The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Archives of Toxicology 92, 2227–2243.


Krajnak, S., Battista, M., Brenner, W., Almstedt, K., Elger, T., Heimes, A.-S., Hasenburg, A., and Schmidt, M. (2018). Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients. Breast Care 13, 272–276.


Loibl, S., Barinoff, J., Seiler, S., Decker, T., Denkert, C., Hardy-Bessard, A.-C., Senkus-Konefka, E., Cognetti, F., Palmieri, C., Gelmon, K., et al. (2018). A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). Cancer Res. 78.


Lorenz, E., Blettner, M., Lange, B., Schmidt, M., Schneider, A., Schwentner, L., Wollschläger, D., and Merzenich, H. (2018). Prevalence of Cardiac Disease in Breast Cancer Patients at Time of Diagnosis Compared to the General Female Population in Germany. Breast Care 13, 264–271.


Merzenich, H., Blettner, M., Niehoff, D., Schwentner, L., Schmidt, M., Schmitt, M., and Wollschläger, D. (2018a). Cardiac late events in German breast cancer patients: a validation study on the agreement between patient self-reports and information from physicians. BMC Cardiovascular Disorders 18.


Merzenich, H., Wollschläger, D., Almstedt, K., Schmidt, M., Blettner, M., Schmidberger, H., and Stockinger, M. (2018b). Kardiale Spätfolgen nach Strahlentherapie und Chemotherapie. Der Onkologe 24, 780–789.


Mobus, V., Mahlberg, R., Janni, W., Tome, O., Marme, F., Forstbauer, H., Reimer, T., von der Assen, A., Reinisch, M., Lorenz, R., et al. (2018). Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. Cancer Res. 78.


Moebus, V., Noeding, S., Ladda, E., Klare, P., Schmidt, M., Schneeweiss, A., Janni, W., Marme, F., Reimer, T., Schmatloch, S., et al. (2018). Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting. J. Clin. Oncol. 36.


Mueller, V., Park-Simon, T.-W., Huober, J., Schmidt, M., Weide, R., Reinisch, M., Fehm, T., Salat, C., Loibl, S., Schem, C., et al. (2018). A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. unresectable locally advanced or metastatic breast cancer: HER2CLIMB. Oncol. Res. Treat. 41, 28–28.


Münster, E., Letzel, S., Passet-Wittig, J., Schneider, N.F., Schuhrke, B., Seufert, R., and Zier, U. (2018). Who is the gate keeper for treatment in a fertility clinic in Germany? -baseline results of a prospective cohort study (PinK study)-. BMC Pregnancy and Childbirth 18.


Pleimes, D., Moebus, V., Mayer, F., Schmidt, M., Asang, C., Flunkert, K., and Mikus, G. (2018). Induced Myerosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups. Blood 132.


Pradella, F., Leimer, B., Fruth, A., Queisser, A., and van Ewijk, R. (2018). Health effects of in utero exposure to Ramadan: A survey study among pregnant Muslim women in Germany. Eur. J. Public Health 28, 487–487.


Reimer, T., Engel, J., Schmidt, M., Offersen, B.V., Smidt, M.L., and Gentilini, O.D. (2018). Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery? Breast Care 13, 324–330.


Reinisch, M., Seiler, S., Hauzenberger, T., Schmatloch, S., Strittmatter, H., Zahm, D.M., Thode, C., Jackisch, C., Furlanetto, J., Strik, D., et al. (2018). Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen plus /- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor plus GnRHa in male breast cancer patients. Cancer Res. 78.


Roseweir, A.K., Bennett, L., Dickson, A., Cheng, K., Quintayo, M.-A., Bayani, J., McMillan, D.C., Horgan, P.G., van de Velde, C.J.H., Seynaeve, C., et al. (2018). Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. JNCI: Journal of the National Cancer Institute 110, 616–627.


Schmidt, M., and Gerlach, C. (2018). Palliativmedizinische Maßnahmen bei gynäkologischen Malignomen und Mammakarzinomen gemäß S3 - Leitlinie. Der Gynäkologe 51, 859–869.


Schmidt, M., and Sebastian, M. (2018). Palbociclib—The First of a New Class of Cell Cycle Inhibitors. In Small Molecules in Oncology, U.M. Martens, ed. (Cham: Springer International Publishing), pp. 153–175.


Schmidt, M., Decker, T., Fehm, T., Fuxius, S., Harbeck, N., Juhasz-Boess, I., Thomssen, C., Seehase, M., Schollenberger, L., Ruckes, C., et al. (2018a). A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus ) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro. Cancer Res. 78.


Schmidt, M., Weyer-Elberich, V., Hengstler, J.G., Heimes, A.-S., Almstedt, K., Gerhold-Ay, A., Lebrecht, A., Battista, M.J., Hasenburg, A., Sahin, U., et al. (2018b). Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research 20.


Schwab, R., Rautenberg, B., Weis, J., and Hasenburg, A. (2018). Schwangerschaft und Krebs: psychoonkologische Beratung zur Fertilität. Der Onkologe 24, 552–555.


Singer, S., Claus, S., Briest, S., Stolzenburg, J.-U., Papsdorf, K., Gockel, I., Köhler, U., Oestreicher, G., Heß, G., Schmidt, M., et al. (2018). Positive und negative Veränderungen im Leben nach der Krebsdiagnose: Eine prospektive Mixed-Method-Studie. Der Onkologe 24, 411–419.


Surowy, H., Varga, D., Burwinkel, B., Marmé, F., Sohn, C., Luedeke, M., Rinckleb, A., Maier, C., Deissler, H., Volcic, M., et al. (2018). A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity: Role of haplotype spanning SLX4/FANCP in BC. International Journal of Cancer 142, 757–768.


Thaler, S., Schad, A., Kirkpatrick, C.J., Sleeman, J.P., Springer, E., Schmidt, M., and Cotarelo, C.L. (2018). Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance. Cancer Res. 78.


Thill, M., and Schmidt, M. (2018). Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology 10, 175883591879332.


Thill, M., Liedtke, C., Müller, V., Janni, W., Schmidt, M., and on behalf of the AGO Breast Committee (2018a). AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care 13, 209–215.


Thill, M., Schmidt, M., Lux, M., Liedtke, C., Schneeweiss, A., and Jackisch, C. (2018b). Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms. Geburtshilfe und Frauenheilkunde 78, 41–44.


Witzel, I., Laakmann, E., Weide, R., Neunhöffer, T., Park-Simon, T.-J., Schmidt, M., Fasching, P.A., Hesse, T., Polasik, A., Mohrmann, S., et al. (2018). Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. European Journal of Cancer 102, 1–9.


Wöckel, A., Festl, J., Stüber, T., Brust, K., Stangl, S., Heuschmann, P., Albert, U.-S., Budach, W., Follmann, M., Janni, W., et al. (2018a). Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe und Frauenheilkunde 78, 927–948.


Wöckel, A., Festl, J., Stüber, T., Brust, K., Krockenberger, M., Heuschmann, P., Jírů-Hillmann, S., Albert, U.-S., Budach, W., Follmann, M., et al. (2018b). Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe und Frauenheilkunde 78, 1056–1088.

2017

Affolter A, Samosny G, Heimes AS, Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A, Brenner W, Mann WJ, Brieger J. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head Neck. 2017 Apr;39(4):623-632

Albrich, S.B., Welker, K., Wolpert, B., Steetskamp, J., Porta, S., Hasenburg, A., and Skala, C. (2017). How common is ballooning? Hiatal area on 3D transperineal ultrasound in urogynecological patients and its association with lower urinary tract symptoms. Arch. Gynecol. Obstet. 295, 103–109.


Almstedt, K., Sicking, I., Battista, M.J., Huangfu, S., Heimes, A.-S., Weyer-Elberich, V., Hasenburg, A., and Schmidt, M. (2017). Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer. Breast Care 12, 329–333.


Barinoff, J., Schmidt, M., Schneeweiss, A., Schoenegg, W., Thill, M., Keitel, S., Lattrich, C.R., Hinke, A., Kutscheidt, A., and Jackisch, C. (2017). Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery. Eur. J. Cancer 83, 116–124.


Bartlett, J., Kalatskaya, I., Yousif, F., Bayani, J., Trinh, Q.M., Heisler, L., Timms, L., Lee, S., Buchner, N., Milacic, M., et al. (2017). Targeted sequencing in a phase III trial of luminal breast cancer: Identification of novel targets. J. Clin. Oncol. 35.


Battista, M.J., Schanz, V., Schmidt, M., Krajnak, S., Elger, T., Heimes, A.S., Maurer, S., Steiner, E., Eichbaum, M., Mallmann, P., et al. (2017). Changes of the Therapeutic Approaches for Endometrial Cancer Patients in Germany Since 2006. Int. J. Gynecol. Cancer 27, 1041–1041.


Baumann, F.T., Hasenburg, A., Jahn, P., Leitzmann, M., Mumm, A., Schulte-Frei, B., and Wiskemann, J. (2017). Excercise is medicine in oncology. On the way to becoming a standard pillar in the treatment of cancer patients. Onkologe 23, 1021–1030.


Bayani, J., Kornaga, E., Crozier, C., Jang, G.H., Kalatskaya, I., Trinh, Q.M., Yao, C.Q., Livingstone, J., Hasenburg, A., Kieback, D.G., et al. (2017a). Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. J. Clin. Oncol. 35.


Bayani, J., Yao, C.Q., Quintayo, M.A., Yan, F., Haider, S., D’Costa, A., Brookes, C.L., van de Velde, C.J.H., Hasenburg, A., Kieback, D.G., et al. (2017b). Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. Npj Breast Cancer 3, UNSP 3.


Breuksch, I., Prosinger, F., Baehr, F., Engelhardt, F.-P., Bauer, H.-K., Thueroff, J.W., Heimes, A.-S., Hasenburg, A., Prawitt, D., and Brenner, W. (2017a). Integrin alpha 5 triggers the metastatic potential in renal cell carcinoma. Oncotarget 8, 107530–107542.


Breuksch, I., Schmidt, M., Hengstler, J., Edlund, K., Gebhard, S., Prawitt, D., Hasenburg, A., and Brenner, W. (2017b). The role of the splice variant PTENdelta in tumor progression. Int. J. Mol. Med. 40, S15–S15.


Dappa, E., Elger, T., Hasenburg, A., Dueber, C., Battista, M.J., and Hoetker, A.M. (2017). The value of advanced MRI techniques in the assessment of cervical cancer: a review. Insights Imaging 8, 471–481.


Eckes, L., Harter, P., Muallem, M.Z., Fuellborn, T., Mustea, A., Dengler, M., Rengsberger, M., Anthuber, C., Emons, G., Weigel, M., et al. (2017a). First Results of the German Prospective Registry for Gynecological Sarcomas (regsa): A Collaboration of Noggo, Ago Study Group, Ago Kommission Ovar, Ago Kommission Uterus, Aro. Int. J. Gynecol. Cancer 27, 1323–1323.


Eckes, L., Harter, P., Muallem, M.Z., Fuellborn, T., Mustea, A., Dengler, M., Rengsberger, M., Anthuber, C., Emons, G., Weigel, M., et al. (2017b). First Results of the German Prospective Registry for Gynecological Sarcomas (regsa): A Collaboration of Noggo, Ago Study Group, Ago Kommission Ovar, Ago Kommission Uterus, Aro. Int. J. Gynecol. Cancer 27, 247–247.


Elger, T., Battista, M., Krajnak, S., Heimes, A.S., Hasenburg, A., and Schmidt, M. (2017a). Weekly Paclitaxel in Refractory Choriocarcinoma. Int. J. Gynecol. Cancer 27, 1324–1324.


Elger, T., Battista, M., Macchiella, D., Krajnak, S., Maurer, S., Hasenburg, A., and Rommens, K. (2017b). Yolk Sac Tumor of the Clitoris in a Fifteen-Months-Old Child. Int. J. Gynecol. Cancer 27, 1325–1325.


Finn, R.S., Crown, J., Lang, I., Boer, K., Bondarenko, I., Kulyk, S.O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2017). Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18). J. Clin. Oncol. 35.


Frees, S., Haber, T., Moskalev, I., Breuksch, I., Struss, W., Thuroff, J., Gleave, M., Prawitt, D., So, A., and Brenner, W. (2017a). The Calcium-Sensing Receptor (casr) Is Responsible for the Development. J. Urol. 197, E792–E792.


Frees, S., Kamal, M., Nestler, S., Bidnur, S., Brenner, W., Jaeger, W., Thomas, C., Neisius, A., Thueroff, J., and Roos, F. (2017b). Are the Current Follow-up Guidelines After Treatment for Organ Confined Renal Cancer Sufficient? J. Urol. 197, E914–E914.


Harbeck, N., Saupe, S., Jaeger, E., Schmidt, M., Kreienberg, R., Mueller, L., Otremba, B.J., Waldenmaier, D., Dorn, J., Warm, M., et al. (2017). A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res. Treat. 161, 63–72.


Hasenburg, A., Farthmann, J., and Schwab, R. (2017a). Sexuality after gynecological cancer. Gynakologe 50, 333–338.


Hasenburg, A., Weis, J., Schwab, R., Kesic, V., Bjelic-Radisic, V., Ottevanger, N., van Dorst, E., Greimel, E., and Mijalkovic, S. (2017b). Psycho-oncology in oncofertility: Fertility and quality of life in cancer patients. Psycho-Oncol. 26, 165–166.


Heimes, A.S., Schmidt, M., Jaekel, J., Almstedt, K., Gebhard, S., Weyer-Elbereich, V., Elger, T., Krajnak, S., Brenner, W., Hasenburg, A., et al. (2017a). A Retrospective Analysis of Immunohistochemical Determined Irf4 (interferon Regulating Factor 4) Expression in a Consecutive Cohort of 114 Ovarian Cancer Patients. Int. J. Gynecol. Cancer 27, 1520–1520.


Heimes, A.-S., Madjar, K., Edlund, K., Battista, M.J., Almstedt, K., Elger, T., Krajnak, S., Rahnenfuehrer, J., Brenner, W., Hasenburg, A., et al. (2017b). Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. Breast Cancer Res. Treat. 165, 293–300.


Heimes, A.-S., Madjar, K., Edlund, K., Battista, M.J., Almstedt, K., Gebhard, S., Foersch, S., Rahnenfuehrer, J., Brenner, W., Hasenburg, A., et al. (2017c). Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J. Cancer Res. Clin. Oncol. 143, 1123–1131.


Heimes, A.-S., Stewen, K., and Hasenburg, A. (2017d). Psychosocial Aspects of Immediate versus Delayed Breast Reconstruction. Breast Care 12, 374–377.


Huss, A., Hasenburg, A., Oehler, M., and Klar, M. (2017a). The Mskcc Nomogram Is More Accurate in the Prediction of Overall Survival in a German Endometrial Cancer Patient Population Than the Figo Staging System. Int. J. Gynecol. Cancer 27, 209–209.


Huss, A., Hasenburg, A., Oehler, M., and Klar, M. (2017b). The Mskcc Nomogram Is More Accurate in the Prediction of Overall Survival in a German Endometrial Cancer Patient Population Than the Figo Staging System. Int. J. Gynecol. Cancer 27, 1111–1111.


Ishibashi, K., Haber, T., Breuksch, I., Gebhard, S., Sugino, T., Kubo, H., Hata, J., Koguchi, T., Yabe, M., Kataoka, M., et al. (2017). Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget 8, 55230–55245.


Klein, E., Beckmann, M.W., Bader, W., Brucker, C., Dobos, G., Fischer, D., Hanf, V., Hasenburg, A., Jud, S.M., Kalder, M., et al. (2017). Gynecologic oncologists’ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. Arch. Gynecol. Obstet. 296, 295–301.


Krajnak, S., Battista, M., Elger, T., Stewen, K., Heimes, A.S., Hasenburg, A., and Schmidt, M. (2017a). Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate. Int. J. Gynecol. Cancer 27, 116–116.


Krajnak, S., Battista, M., Elger, T., Stewen, K., Heimes, A.S., Hasenburg, A., and Schmidt, M. (2017b). Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate. Int. J. Gynecol. Cancer 27, 636–636.


Maurer, S., Elger, T., Krajnak, S., Heimes, A.S., Teifke, A., Kohlwes, E., Hasenburg, A., and Johannes, B.M. (2017). Axillary Schwannoma Imitating Axillary Cyst. Int. J. Gynecol. Cancer 27, 1298–1298.


Merzenich, H., Bartkowiak, D., Schmidberger, H., Schmidt, M., Schwentner, L., Wiegel, T., Woeckel, A., Wollschlaeger, D., and Blettner, M. (2017). 3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Breast Cancer Res. Treat. 161, 143–152.


Moebus, V., Hell, S., and Schmidt, M. (2017). Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer. Geburtshilfe Frauenheilkd. 77, 1079–1087.


Sagheb, K., Manz, A., Albrich, S.B., Taylor, K.J., Hess, G., and Walter, C. (2017). Supraclavicular Metastases from Distant Primary Solid Tumours: A Retrospective Study of 41 Years. J. Maxillofac. Oral. Surg. 16, 152–157.


Schmidt, M., Madjar, K., Heimes, A.-S., Battista, M., Lebrecht, A., Almsetdt, K., Hasenburg, A., Rahnenfhrer, J., and Hengstler, J.G. (2017). Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer. Cancer Res. 77.


Schwab, R., Battista, M.J.B., Kuenzel, K., Dionysopoulou, A., Bake, V., and Hasenburg, A. (2017). A Case of Uterine Relapse in a Young Woman with a History of All (acute Lymphoblastic Leukemia). Int. J. Gynecol. Cancer 27, 995–995.


Seidmann, L., Kamyshanskiy, Y., Martin, S.Z., Fruth, A., and Roth, W. (2017). Immaturity for gestational age of microvasculature and placental barrier in term placentas with high weight. Eur. J. Obstet. Gynecol. Reprod. Biol. 215, 134–140.


Thaler, S., Schmidt, M., Thiede, G., Schad, A., and Sleeman, J.P. (2017a). Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Cancer Res. 77.


Thaler, S., Schmidt, M., Rosswag, S., Thiede, G., Schad, A., and Sleeman, J.P. (2017b). Proteasome inhibitors prevent bi-directional HER2/estrogenreceptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget 8, 72281–72301.


Thill, M., Liedtke, C., Solomayer, E.-F., Mueller, V., Janni, W., and Schmidt, M. (2017). AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017. Breast Care 12, 184–191.

2016

Albrich, S., Steetskamp, J., Knoechel, S.-L., Porta, S., Hoffmann, G., and Skala, C. (2016). Assessment of pelvic floor muscle contractility: digital palpation versus 2D and 3D perineal ultrasound. Arch. Gynecol. Obstet. 293, 839–843.


Almstedt, K., and Schmidt, M. (2016). Immunotherapies for Breast Cancer - How Immune System and Cancer are associated and on what the Research works? Geburtshilfe Frauenheilkd. 76, 503–506.


Almstedt, K., Sicking, I., Huangfu, S., van de Sandt, L., Battista, M., Heimes, A.-S., Lebrecht, A., Hoffmann, G., Rahnenfuehrer, J., Hengstler, J., et al. (2016). Prognostic significance of focal adhesion kinase (FAK) in node-negative breast cancer (microarray based gene-expression- and immunohistochemistry-data). Oncol. Res. Treat. 39, 4–4.


Bartlett, J.M.S., Christiansen, J., Gustavson, M., Rimm, D.L., Piper, T., van de Velde, C.J.H., Hasenburg, A., Kieback, D.G., Putter, H., Markopoulos, C.J., et al. (2016). Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Arch. Pathol. Lab. Med. 140, 66–74.


Battista, M.J., and Schmidt, M. (2016). Fulvestrant for the treatment of endometrial cancer. Expert Opin. Investig. Drugs 25, 475–483.


Battista, M.J., Almstedt, K., Heimes, A.-S., Schmidt, M., Hoffmann, G., Eichbaum, M., Mallmann, P., and Steiner, E. (2016a). Management of recurrent and metastatic endometrial cancer in Germany: Results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Oncol. Res. Treat. 39, 98–98.


Battista, M.J., Cotarelo, C., Almstedt, K., Heimes, A.-S., Makris, G.-M., Weyer, V., and Schmidt, M. (2016b). Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients. Arch. Gynecol. Obstet. 294, 599–606.


Battista, M.J., Goetze, K., Schmidt, M., Cotarelo, C., Weyer-Elberich, V., Hasenburg, A., Mueller-Klieser, W., and Walenta, S. (2016c). Feasibility of induced metabolic bioluminescence imaging in advanced ovarian cancer patients: first results of a pilot study. J. Cancer Res. Clin. Oncol. 142, 1909–1916.


Battista, M.J., Schmidt, M., Jakobi, S., Cotarelo, C., Almstedt, K., Heimes, A.-S., Makris, G.-M., Weyer, V., Lebrecht, A., Hoffmann, G., et al. (2016d). c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients. Oncol. Lett. 12, 2001–2007.


Bauer, H.-K., Heller, M., Fink, M., Maresch, D., Gartner, J., Gassner, U.M., and Al-Nawas, B. (2016). Social and legal frame conditions for 3D (and) bioprinting in medicine. Int. J. Comput. Dent. 19, 293–299.


Bayani, J., Yao, C.Q., Quintayo, M.A., Haider, S., Brookes, C.L., Yan, F., van de Velde, C.J.H., Hasenburg, A., Kieback, D.G., Markopoulos, C., et al. (2016). Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial. Cancer Res. 76.
du Bois, A., Ewald-Riegler, N., de Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., Kommoss, F., Schmalfeldt, B., Hilpert, F., Fehm, T., et al. (2016). Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynakologische Onkologie AGO Study Group (vol 49, pg 1905, 2013). Eur. J. Cancer 65, 192–193.


Breuksch, I., Weinert, M., and Brenner, W. (2016). The role of extracellular calcium in bone metastasis. J. Bone Oncol. 5, 143–145.


Cotarelo, C.L., Schad, A., Kirkpatrick, C.J., Sleeman, J.P., Springer, E., Schmidt, M., and Thaler, S. (2016). Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. Oncotarget 7, 74846–74859.


Farthmann, J., and Hasenburg, A. (2016). Oncology Sexuality after gynecological oncology Cancer and Breast Cancer. Geburtshilfe Frauenheilkd. 76, 231–233.


Farthmann, J., Hanjalic-Beck, A., Veit, J., Rautenberg, B., Stickeler, E., Erbes, T., Foeldi, M., and Hasenburg, A. (2016). The impact of chemotherapy for breast cancer on sexual function and health-related quality of life. Support. Care Cancer 24, 2603–2609.


Finn, R.S., Crown, J.P., Ettl, J., Schmidt, M., Bondarenko, I.M., Lang, I., Pinter, T., Boer, K., Patel, R., Randolph, S., et al. (2016). Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 18, 67.


Gomez, R., Schorsch, M., Hahn, T., Henke, A., Hoffmann, I., Seufert, R., and Skala, C. (2016). The influence of AMH on IVF success. Arch. Gynecol. Obstet. 293, 667–673.


Heimes, A.-S., van de Sandt, L., Edlund, K., Battista, M., Sicking, I., Almstedt, K., Lebrecht, A., Rahnenfuehrer, J., Hengstler, J.G., and Schmidt, M. (2016). Prognostic impact of interferon regulating factor 4 (IRF4) in node-negative breast cancer. Oncol. Res. Treat. 39, 45–45.


Heller, M., Bauer, H.-K., Goetze, E., Gielisch, M., Roth, K.E., Maier, G.S., Drees, P., Dorweiler, B., Ghazy, A., Neufurth, M., et al. (2016a). Applications of patient-specific 3D printing in medicine. Int. J. Comput. Dent. 19, 323–339.


Heller, M., Bauer, H.-K., Goetze, E., Gielisch, M., Ozbolat, I.T., Moncal, K.K., Rizk, E., Seitz, H., Gelinsky, M., Schrder, H.C., et al. (2016b). Materials and scaffolds in medical 3D printing and bioprinting in the context of bone regeneration. Int. J. Comput. Dent. 19, 301–321.


Hellwig, B., Madjar, K., Edlund, K., Marchan, R., Cadenas, C., Heimes, A.-S., Almstedt, K., Lebrecht, A., Sicking, I., Battista, M.J., et al. (2016). Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy. PLoS One 11, e0167585.


Hilbert, F., Gropp-Meier, M., Schmalfeldt, B., Rau, J., Meier, W., Hasenburg, A., Belau, A., Vergote, I., Zorr, A., Hils, R., et al. (2016). Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy +/- pertuzumab for platinum-resistant ovarian cancer (PROC). Oncol. Res. Treat. 39, 138–138.


Kalder, M., Mueller, T., Fischer, D., Mueller, A., Bader, W., Beckmann, M.W., Brucker, C., Hack, C.C., Hanf, V., Hasenburg, A., et al. (2016). A Review of Integrative Medicine in Gynaecological Oncology. Geburtshilfe Frauenheilkd. 76, 150–155.


Kidszun, A., Linebarger, J., Walter, J.K., Paul, N.W., Fruth, A., Mildenberger, E., and Lantos, J.D. (2016). What If the Prenatal Diagnosis of a Lethal Anomaly Turns Out to Be Wrong? Pediatrics 137, e20154514.
Klar, M., Hasenburg, A., Hasanov, M., Hilpert, F., Meier, W., Pfisterer, J., Pujade-Lauraine, E., Herrstedt, J., Reuss, A., and du Bois, A. (2016). Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. Eur. J. Cancer 66, 114–124.


Laakmann, E., Witzel, I., Fehm, T., Hesse, I., von Minckwitz, G., Moebus, V., Park-Simon, T.-W., Neunhoeffer, I., Schmidt, M., Loibl, S., et al. (2016). Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): The introduction of the multicenter register and analysis of patient data. Oncol. Res. Treat. 39, 50–50.


Lambers, K., Hasenburg, A., Stickeler, E., Gitsch, G., Grosu, A.L., Henne, K., and Farthmann, J. (2016). Customized treatment of recurrent gynaecological cancer - the need for intraoperative radiation therapy. Eur. J. Gynaecol. Oncol. 37, 48–52.


Loibl, S., Furlanetto, J., Barinoff, J., Bauerschlag, D., Herr, D., Luebbe, K., Maass, N., Mueller, V., Mundhenke, C., Schmidt, M., et al. (2016). DESIREE - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer. Cancer Res. 76.


Mahner, S., Lueck, H.-J., Grischke, E.-M., Rau, J., Gropp-Meier, M., Schmalfeldt, B., Meier, W., Hasenburg, A., Belau, A., Vergote, I., et al. (2016). Chemotherapy (CT) +/- pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial. Oncol. Res. Treat. 39, 97–97.


Makris, G.M., Poulakaki, N., Battista, M.J., Boehm, D., Petraki, K., Bafaloukos, D., Sergentanis, T., Siristatidis, C., Chrelias, C., and Papantoniou, N. (2016a). Recurrence In Ductal Carcinoma In Situ And Molecular Subtypes. Int. J. Gynecol. Cancer 26, 49–50.


Makris, G.-M., Charalampopoulos, A., Siristatidis, C., Fexi, D., Chrelias, C., Battista, M.-J., and Papantoniou, N. (2016b). Y-type Anovulvar Fistula Complicating Inflammatory Bowel Disease. Am. Surg. 82, E305–E307.


Marme, F., Grischke, E.-M., Gropp-Meier, M., Rau, J., Schmalfeldt, B., Meier, W., Hasenburg, A., Belau, A., Vergote, I., Zorr, A., et al. (2016). Biomarker results from PENELOPE, A randomised phase III trial evaluating chemotherapy (CT) +/- pertuzumab (P) for platinum-resistant ovarian cancer (PROC) with low tumor HER3 mRNA expression. Oncol. Res. Treat. 39, 94–94.


Pannenbeckers, M., Derigs, P., Fruth, A., Paschen, A., Woelfel, T., and Woelfel, C. (2016). Detection of HLA-independent tumor-reactive T cells in umbilical cord blood. Oncol. Res. Treat. 39, 137–137.


Poulakaki, N., Makris, G.-M., Battista, M.-J., Boehm, D., Petraki, K., Bafaloukos, D., Sergentanis, T.N., Siristatidis, C., Chrelias, C., and Papantoniou, N. (2016). Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast? Breast 25, 57–61.


Radosa, J.C., Radosa, C.G., Kastl, C., Mavrova, R., Gabriel, L., Graeber, S., Wagenpfeil, G., Baum, S., Hamza, A., Joukhadar, R., et al. (2016). Influence of the Preoperative Decision-Making Process on the Postoperative Outcome after Hysterectomy for Benign Uterine Pathologies. Geburtshilfe Frauenheilkd. 76, 383–389.


Reif, R., Adawy, A., Vartak, N., Schroeder, J., Guenther, G., Ghallab, A., Schmidt, M., Schormann, W., and Hengstler, J.G. (2016). Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells. J. Biol. Chem. 291, 3837–3847.


Schmidt, M. (2016a). Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index. Breast Care 11, 22–26.


Schmidt, M. (2016b). Palbociclib - from Bench to Bedside and Beyond. Breast Care 11, 177–181.
Schmidt, M., van de Sandt, L., Heimes, A.-S., Battista, M., Lebrecht, A., Almstedt, K., Hoffmann, G., Rahnenfuehrer, J., and Hengstler, J.G. (2016a). Prognostic significance of immune checkpoint receptors in node-negative breast cancer. Cancer Res. 76.


Schmidt, M., Thomssen, C., and Untch, M. (2016b). Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis. Oncol. Res. Treat. 39, 102–110.


Schneeweiss, A., Forster, F., Tesch, H., Aktas, B., Gluz, O., Geberth, M., Hertz-Eichenrode, M.M., Schonegg, W., Schumacher, C., Kutscheidt, A., et al. (2016). First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. Anticancer Res. 36, 967–974.


Schneider, M., Schmeh, I., Fruth, A., Whybra-Truempler, C., and Mildenberger, E. (2016). Female Preterm Monozygotic Twins Discordant for Fetal Megacystis due to Cloacal Dysgenesis After Conception by Intracytoplasmatic Sperm Injection - Case Report and Review of Literature. Z. Geburtsh. Neonat. 220, 223–227.


Schnuerch, H.G., Ackermann, S., Alt, C.D., Barinoff, J., Boeing, C., Dannecker, C., Gieseking, F., Guenthert, A., Hantschmann, P., Horn, L.C., et al. (2016). Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015. Geburtshilfe Frauenheilkd. 76, 1035–1048.


Thiel, F.C., Parvanta, P., Hein, A., Mehlhorn, G., Lux, M.P., Renner, S.P., Preisner, A., Beckmann, M.W., and Schrauder, M.G. (2016). Chylous Ascites After Lymphadenectomy for Gynecological Malignancies. J. Surg. Oncol. 114, 613–618.


Van der Ven, H., Liebenthron, J., Beckmann, M., Toth, B., Korell, M., Kruessel, J., Frambach, T., Kupka, M., Hohl, M.K., Winkler-Crepaz, K., et al. (2016). Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum. Reprod. 31, 2031–2041.


Vdovichenko, N., Ataseven, B., Heitz, F., Prader, S., Schneider, S., Kurzeder, C., Heikaus, S., Weikel, W., Fisseler-Eckhoff, A., Alexander, T., et al. (2016). Fertility-sparing surgery (FSS) in patients with borderline ovarian tumors (BOT). Oncol. Res. Treat. 39, 92–92.


Witzel, I., Loibl, S., Laakmann, E., Augustin, D., Flock, F., Dohmen, H.-H., Durmus, G., Frank, M., Hesse, T., Ignatov, A., et al. (2016). Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry. Cancer Res. 76.


Woelber, L., Griebel, L.-F., Eulenburg, C., Sehouli, J., Jueckstock, J., Hilpert, F., de Gregorio, N., Hasenburg, A., Ignatov, A., Hillemanns, P., et al. (2016). Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynakologische Onkologie CaRE-1 multicenter study. Eur. J. Cancer 69, 180–188.


Zhang, Y., Zhao, X., Leonhart, R., Nadig, M., Hasenburg, A., Wirsching, M., and Fritzsche, K. (2016). A cross-cultural comparison of climacteric symptoms, self-esteem, and perceived social support between Mosuo women and Han Chinese women. Menopause-J. N. Am. Menopause Soc. 23, 784–791.

2015

Albrich, S., Rommens, K., Steetskamp, J., Weyer, V., Hoffmann, G., Skala, C., and Zahn, E. (2015a). Prevalence of Levator Ani Defects in Urogynecological Patients. Geburtshilfe Frauenheilkd. 75, 51–55.
Albrich, S.B., Shek, K., Krahn, U., and Dietz, H.P. (2015b). Measurement of subpubic arch angle by three-dimensional transperineal ultrasound and impact on vaginal delivery. Ultrasound Obstet. Gynecol. 46, 496–500.


Almstedt, K., and Schmidt, M. (2015). Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care 10, 168–172.


Battista, M.J., Schmidt, M., Eichbaum, M., Almstedt, K., Heimes, A.-S., Mallmann, P., Hoffmann, G., and Steiner, E. (2015a). Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch. Gynecol. Obstet. 292, 1355–1360.


Battista, M.J., Schmidt, M., Rieks, N., Sicking, I., Albrich, S., Eichbaum, M., Koelbl, H., Mallmann, P., Hoffmann, G., and Steiner, E. (2015b). Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. J. Cancer Res. Clin. Oncol. 141, 555–562.


Denkert, C., von Minckwitz, G., Brase, J.C., Sinn, B.V., Gade, S., Kronenwett, R., Pfitzner, B.M., Salat, C., Loi, S., Schmitt, W.D., et al. (2015). Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J. Clin. Oncol. 33, 983–991.


Eichbaum, M.H.R., Schmidt, M., Grischke, E.-M., Gebauer, G., Fricke, H.-C., Lenz, F., Bischofs, E., Wallwiener, M., Marme, F., Schneeweiss, A., et al. (2015). The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer. J. Clin. Oncol. 33.


Finn, R.S., Crown, J., Lang, I., Kulyk, S.O., Schmidt, M., Patel, R., Thummala, A., Bondarenko, I., Randolph, S., Kim, S., et al. (2015a). The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. J. Clin. Oncol. 33.


Finn, R.S., Crown, J.P., Lang, I., Boer, K., Bondarenko, I.M., Kulyk, S.O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015b). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25–35.


Karn, T., Pusztai, L., Liedtke, C., Bianchini, G., Gyoerffy, B., Hatzis, C., Rody, A., Mueller, V., Schmidt, M., Holtrich, U., et al. (2015). Gene expression associated with poor prognosis of young TNBC patients. Cancer Res. 75.


Laterza, R.M., Schrutka, L., Umek, W., Albrich, S., and Koelbl, H. (2015). Pelvic floor dysfunction after levator trauma 1-year postpartum: a prospective case-control study. Int. Urogynecol. J. 26, 41–47.
Lohr, M., Hellwig, B., Edlund, K., Mattsson, J.S.M., Botling, J., Schmidt, M., Hengstler, J.G., Micke, P., and Rahnenfuehrer, J. (2015). Identification of sample annotation errors in gene expression datasets. Arch. Toxicol. 89, 2265–2272.


Sahu, S.K., Garding, A., Tiwari, N., Thakurela, S., Toedling, J., Gebhard, S., Ortega, F., Schmarowski, N., Berninger, B., Nitsch, R., et al. (2015). JNK-dependent gene regulatory circuitry governs mesenchymal fate. Embo J. 34, 2162–2181.


Schmidt, M., van de Sandt, L., Almstedt, K., Battista, M.J., Heimes, A.-S., Lebrecht, A., Hoffmann, G., Rahnenfuehrer, J., and Hengstler, J.G. (2015a). Prognostic significance of Focal Adhesion Kinase (FAK) in node-negative breast cancer. J. Clin. Oncol. 33.


Schmidt, M., van de Sandt, L., Edlund, K., Sicking, I., Battista, M., Heimes, A.-S., Lebrecht, A., Hoffmann, G., Gehrmann, M., Rahnenfuehrer, J., et al. (2015b). Prognostic significance of the interferon metagene in node-negative breast cancer depends on the molecular subtype. Cancer Res. 75.


Slamon, D.J., Crown, J., Lang, I., Kulyk, S.O., Schmidt, M., Patel, R., Thummala, A., Voytko, N.L., Randolph, S., Kim, S., et al. (2015). Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2-advanced breast cancer (ABC) (PALOMA-1/TRIO-18). J. Clin. Oncol. 33.


Stock, A.-M., Klee, F., Edlund, K., Grinberg, M., Hammad, S., Marchan, R., Cadenas, C., Niggemann, B., Zaenker, K.S., Rahnenfuehrer, J., et al. (2015). Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer. Anticancer Res. 35, 5277–5285.


Thaler, S., Thiede, G., Hengstler, J.G., Schad, A., Schmidt, M., and Sleeman, J.P. (2015). The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Int. J. Cancer 137, 686–697.

2014

Battista, M.J., Cotarelo, C., Jakobi, S., Steetskamp, J., Makris, G., Sicking, I., Weyer, V., and Schmidt, M. (2014a). Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients. J. Cancer Res. Clin. Oncol. 140, 1097–1102.


Battista, M.J., Mantai, N., Sicking, I., Cotarelo, C., Weyer, V., Lebrecht, A., Solbach, C., and Schmidt, M. (2014b). Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. Oncol. Rep. 31, 2213–2219.


Battista, M.J., Schmidt, M., Rieks, N., Steetskamp, J., Sicking, I., Lebrecht, A., Koelbl, H., Mallmann, P., Hoffmann, G., and Steiner, E. (2014c). Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: Results of the AGO pattern of care studies from the years 2013, 2009, and 2006. J. Cancer Res. Clin. Oncol. 140, 2087–2093.


Boettcher, B., Laterza, R.M., Wildt, L., Seufert, R.J., Buhling, K.J., Singer, C.F., Hill, W., Griffin, P., Jilma, B., Schulz, M., et al. (2014). A first-in-human study of PDC31 (prostaglandin F-2 alpha receptor inhibitor) in primary dysmenorrhea. Hum. Reprod. 29, 2465–2473.


Cadenas, C., van de Sandt, L., Edlund, K., Lohr, M., Hellwig, B., Marchan, R., Schmidt, M., Rahnenfuehrer, J., Oster, H., and Hengstler, J.G. (2014). Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle 13, 3282–3291.


Godoy, P., Cadenas, C., Hellwig, B., Marchan, R., Stewart, J., Reif, R., Lohr, M., Gehrmann, M., Rahnenfuehrer, J., Schmidt, M., et al. (2014). Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer 21, 491–499.


Gomez, R., Schorsch, M., Steetskamp, J., Hahn, T., Heidner, K., Seufert, R., and Skala, C.E. (2014). The effect of ovarian stimulation on the outcome of intrauterine insemination. Arch. Gynecol. Obstet. 289, 181–185.


Heitz, F., Amant, F., Fotopoulou, C., Battista, M.J., Wimberger, P., Traut, A., Fisseler-Eckhoff, A., Harter, P., Vandenput, I., Sehouli, J., et al. (2014). Synchronous Ovarian and Endometrial Cancer-an International Multicenter Case-Control Study. Int. J. Gynecol. Cancer 24, 54–60.


Honig, A., Gehrmann, M., Kranke, P., Keller, D., Engel, J.B., Hengstler, J., and Schmidt, M. (2014). Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer. Eur. J. Gynaecol. Oncol. 35, 503–507.


Jackisch, C., Welslau, M., Schoenegg, W., Selbach, J., Harich, H.-D., Schroeder, J., Schmidt, M., Goehler, T., Eustermann, H., Ringel, R., et al. (2014). Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - Results from a prospective, observational study in Germany. Breast 23, 603–608.


Kuhtz, J., Schneider, E., El Hajj, N., Zimmermann, L., Fust, O., Linek, B., Seufert, R., Hahn, T., Schorsch, M., and Haaf, T. (2014). Epigenetic heterogeneity of developmentally important genes in human sperm: Implications for assisted reproduction outcome. Epigenetics 9, 1648–1658.


Mayer, A., Schmidt, M., Seeger, A., Serras, F.A., Vaupel, P., and Schmidberger, H. (2014a). Microregional mismatch of markers related to hypoxia and the Warburg effect in squamous cell carcinomas of the vulva. Strahlenther. Onkol. 190, 82–83.


Mayer, A., Schmidt, M., Seeger, A., Serras, A.F., Vaupel, P., and Schmidberger, H. (2014b). GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva. BMC Cancer 14, 760.


Milde-Langosch, K., Karn, T., Schmidt, M., Eulenburg, C.Z., Oliveira-Ferrer, L., Wirtz, R.M., Schumacher, U., Witzel, I., Schuetze, D., and Mueller, V. (2014). Prognostic relevance of glycosylation-associated genes in breast cancer. Breast Cancer Res. Treat. 145, 295–305.


Schmidt, M. (2014). Chemotherapy in Early Breast Cancer: When, How and Which One? Breast Care 9, 154–160.


Schmidt, M., and Untch, M. (2014). Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved. Ann. Oncol. 25, 754–754.


Schmidt, M., Hellwig, B., Sicking, I., Battista, M., Gebhard, S., Lebrecht, A., Gehrmann, M., Wirtz, R., Hoffmann, G., Solbach, C., et al. (2014). Comparison of the prognostic significance of immunoglobulin kappa C, CD4 and CD8 in node-negative breast cancer. Oncol. Res. Treat. 37, 2–2.


Schorsch, M., Hahn, T., Turley, H., and Seufert, R. (2014). Blastocyst formation, pregnancy and birth (more than 10 years after the birth of the first child from the same IVF cycle), derived from human PN-stage cryopreserved for 10 years. Arch. Gynecol. Obstet. 289, 227–228.


Sicking, I., Edlund, K., Wesbuer, E., Weyer, V., Battista, M.J., Lebrecht, A., Solbach, C., Grinberg, M., Lotz, J., Hoffmann, G., et al. (2014a). Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients. PLoS One 9, e111306.


Sicking, I., Rommens, K., Battista, M.J., Boehm, D., Gebhard, S., Lebrecht, A., Cotarelo, C., Hoffmann, G., Hengstler, J.G., and Schmidt, M. (2014b). Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients. BMC Cancer 14, 952.


Tunn, R., Albrich, S., Beilecke, K., Kociszewski, J., Lindig-Knopke, C., Reisenauer, C., Schwertner-Tiepelmann, N., Kuhn, A., Viereck, V., Radisic, V.B., et al. (2014). Interdisciplinary S2k Guideline: Sonography in Urogynecology Short Version - AWMF Registry Number: 015/055. Geburtshilfe Frauenheilkd. 74, 1093–1098.


Wege, A.K., Schmidt, M., Ueberham, E., Ponnath, M., Ortmann, O., Brockhoff, G., and Lehmann, J. (2014). Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice A novel approach to generate tumor cell specific human antibodies. MAbs 6, 968–977.

2013

Barinoff, J., Traut, A., Bauerschlag, D., Bischoff, J., Herr, D., Luebbe, K., Lueck, H.-J., Maass, N., Mundhenke, C., Schmidt, M., et al. (2013). Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. Geburtshilfe Frauenheilkd. 73, 433–439.


Battista, M., Mantai, N., Makris, G., Sicking, I., Weyer, V., Cotarelo, C., and Schmidt, M. (2013a). Proliferation (ki-67) and Endocrine Regulation (progesterone Receptor) Correlate with Prognosis in Ovarian Cancer - Invasion (upa and Pai-1) Does Not. Int. J. Gynecol. Cancer 23.


Battista, M.J., Steiner, E., Rieks, N., Steetskamp, J., Seeger, A., Sicking, I., Boehm, D., Schmidt, M., and Koelbl, H. (2013b). Nationwide Analysis on Surgical Staging Procedures and Systemic Treatment for Patients With Endometrial Cancer in Germany. Int. J. Gynecol. Cancer 23, 105–112.


Bianchini, G., Pusztai, L., Karn, T., Iwamoto, T., Rody, A., Kelly, C.M., Mueller, V., Schmidt, M., Qi, Y., Holtrich, U., et al. (2013). Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res. 15, R86.


Dubsky, P., Brase, J.C., Jakesz, R., Rudas, M., Singer, C.F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., et al. (2013a). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br. J. Cancer 109, 2959–2964.


Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C.F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., et al. (2013b). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann. Oncol. 24, 640–647.


Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., Sweep, C.G.J., Lisboa, B.W., Lux, M.P., Beck, T., et al. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49, 1825–1835.


Heitz, F., Amant, F., Fotopoulou, C., Battista, M.J., Wimberger, P., Vandenput, I., Sehouli, J., Schmidt, M., Kimmig, R., and du Bois, A. (2013). Synchronous Ovarian and Endometrial Cancer - an International Multicenter Case-Control Study. Int. J. Gynecol. Cancer 23.


Kneist, W., Kauff, D.W., Naumann, G., and Lang, H. (2013). Resection rectopexy-laparoscopic neuromapping reveals neurogenic pathways to the lower segment of the rectum: preliminary results. Langenbecks Arch. Surg. 398, 565–570.


Lehr, H.-A., Rochat, C., Schaper, C., Nobile, A., Shanouda, S., Vijgen, S., Gauthier, A., Obermann, E., Leuba, S., Schmidt, M., et al. (2013). Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas. Mod. Pathol. 26, 336–342.


Maass, N., Harbeck, N., Mundhenke, C., Lerchenmueller, C., Barinoff, J., Lueck, H.-J., Ettl, J., Aktas, B., Kuemmel, S., Roesel, S., et al. (2013). Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J. Cancer Res. Clin. Oncol. 139, 2047–2056.


Milde-Langosch, K., Karn, T., Mueller, V., Witzel, I., Rody, A., Schmidt, M., and Wirtz, R.M. (2013). Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res. Treat. 137, 57–67.


von Minckwitz, G., Martin, M., Wilson, G., Alba, E., Schmidt, M., Biganzoli, L., and Awada, A. (2013a). Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit. Rev. Oncol./Hematol. 85, 315–331.


von Minckwitz, G., Moebus, V., Schneeweiss, A., Huober, J., Thomssen, C., Untch, M., Jackisch, C., Diel, I.J., Elling, D., Conrad, B., et al. (2013b). German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. J. Clin. Oncol. 31, 3531–3539.


Rodriguez-Lescure, A., Brase, J.C., Schmidt, M., Gehrmann, M., Ruiz, A., Ruiz Borrego, M., Munarriz, B., Rodriguez, C.A., Calvo, L., and Martin, M. (2013). Biomarkers for predicting taxane efficacy in ER+/HER2-breast cancer patients: From in-vitro chemosensitivity screening to clinical validation in the GEICAM/ 9906 trial. Eur. J. Cancer 49, S475–S475.


Schmidt, M. (2013). Gene expression signatures in breast cancer. Onkologe 19, 465–+.
Schmidt, M., Micke, P., and Hengstler, J.G. (2013). IGKC and Prognosis in Breast Cancer-Letter. Clin. Cancer Res. 19, 304–304.


Schuetze, D., Milde-Langosch, K., Witzel, I., Rody, A., Karn, T., Schmidt, M., Choschzick, M., Jaenicke, F., and Muller, V. (2013). Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer. J. Cancer Res. Clin. Oncol. 139, 747–754.


Wagner, M., Koslowski, M., Paret, C., Schmidt, M., Tuereci, O., and Sahin, U. (2013). NCOA3 is a selective co-activator of estrogen receptor alpha-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer 13, 570.


Witzel, I., Graeser, M., Karn, T., Schmidt, M., Wirtz, R., Schuetze, D., Rausch, A., Jaenicke, F., Milde-Langosch, K., and Mueller, V. (2013). Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J. Cancer Res. Clin. Oncol. 139, 809–816.